24-Week Clinical Study Reports Favourable Safety Profile for Specific Ashwagandha Extract
A 24-week, randomised, double-blind, placebo-controlled clinical study has reported a favourable safety and tolerability profile for a specific ashwagandha root extract (Shoden®) in healthy adults. Published in 'Phytotherapy Research', the findings provide long-term safety data relevant for dietary supplement manufacturers and formulators.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
A new clinical study has provided further evidence regarding the long-term safety and tolerability of ashwagandha (Withania somnifera) root extract. The randomised, double-blind, placebo-controlled trial evaluated the extract's profile in healthy adult participants.
Ashwagandha is a widely utilised adaptogenic ingredient in the dietary supplement sector, frequently incorporated into formulations. Its expanding market presence has led to increased interest in robust data concerning its long-term safety and efficacy. This latest study contributes data for manufacturers, formulators, and brand owners focused on product safety and regulatory compliance.
## Study Design and Findings
The research involved healthy adults who were administered a daily dose of ashwagandha extract or a placebo over an extended period. The study design, encompassing a double-blind, randomised, and placebo-controlled methodology, aimed to minimise bias and ensure robust data collection on safety parameters.
The study reported no significant adverse events attributable to the ashwagandha extract. Key safety indicators, including various blood parameters and vital signs, showed no clinically significant changes when compared to the placebo group. Comprehensive adverse event reporting during the trial further supported the extract's tolerability.
## Implications for the Supplement Industry
These findings contribute to the scientific evidence base on ashwagandha, specifically addressing its safety profile over an extended period. For the supplement industry, such data is relevant for product development, substantiation, and marketing. It can help inform discussions regarding ashwagandha-containing products, particularly as interest in adaptogens continues globally.
The general implications for the safety assessment of ashwagandha extracts are noteworthy. Industry stakeholders often seek such long-term data to inform compliance with evolving safety standards and to provide scientific backing for product claims related to safety and tolerability.